Navigation Links
InnoPharma Completes $15 Million Series A Financing
Date:12/1/2011

PISCATAWAY, N.J., Dec. 1, 2011 /PRNewswire/ -- InnoPharma, Inc., a developer of sterile generic and specialty pharmaceutical products, announced that it has completed a $15 million Series A round of private financing. This financing was led by Thomas, McNerney & Partners.

"We are very pleased that InnoPharma's aggressive and well-managed growth over the last few years has allowed us to attract an outstanding investor, whose expertise and professional network will add tremendous value to InnoPharma," stated Navneet Puri, Ph.D., Founder, President, and Chief Executive Officer of InnoPharma. "The funds raised in this financing will allow us to accelerate the development of our product pipeline and also maximize the value that we offer to our customers and end users."

As a result of the financing, two new members have joined InnoPharma's board of directors: Alex Zisson and James Thomas, both partners at Thomas, McNerney & Partners.  The new board of directors will also include Navneet Puri, Raman Kapur, the former CEO of Warrick Pharmaceuticals, and Peter Werth, the CEO of ChemWerth.

"We're very excited to be partnering with InnoPharma.  The company's track record of FDA filings, approvals and partnerships is very impressive, and the additional resources will help InnoPharma maximize the true potential of its pipeline," said Alex Zisson.

Ledgemont Capital Group, LLC, served as the company's placement agent, and Lowenstein Sandler PC served as the company's legal counsel. Thomas, McNerney & Partners was represented by Goodwin Procter LLP.

About INNOPHARMA:

INNOPHARMA is a developer of sterile generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities.  INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.  More information about INNOPHARMA can be found at www.innopharmallc.com.  

About Thomas, McNerney & Partners

Thomas, McNerney & Partners is a health care private equity firm that invests in life science and medical technology companies. Employing a multi-stage investment approach, Thomas, McNerney & Partners has $600 million in assets under management and provides seed and early stage funding to help entrepreneurs launch companies, as well as growth capital to emerging companies for furthering clinical development or for expansion of product commercialization. For more information, please visit: http://www.tm-partners.com/.


'/>"/>
SOURCE INNOPHARMA LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. Agendia Successfully Completes Bi-Annual FDA Inspection
3. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
4. Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc
5. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
6. Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers
7. AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API
8. Peloton Therapeutics Completes $18 Million Series A Financing
9. Sinapis Pharma Completes Phase I Trial
10. MiMedx Group Completes $5,000,000 Private Placement
11. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building ... challenges for companies around the world, such as Illumina, HP and Qualcomm, and is ranked ... its increasing popularity is due to its new team building format, a way for teams ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
(Date:3/23/2017)... March 23, 2017  GlobeImmune, Inc. today announced it ... sale of 12,835,490 shares of its common stock to ... companies. In connection with the sale of its common stock, ... and issue to GlobeImmune 200,000 shares, an estimated $2.0 ... "We are pleased to enter into this strategic ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... recently selected by the Connecticut Technology Council (CTC) as a 2017 Women of ... thirteenth annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished ...
Breaking Biology Technology:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
Breaking Biology News(10 mins):